ADMA Biologics (ADMA) Q2 FY26 earnings call

ADMA Biologics delivered a strong second quarter, marked by accelerating demand for ASCENIV, which continues to drive revenue growth and margin expansion. The company is leveraging its robust financial position to execute on capital allocation priorities, including share repurchases, while advancing its SG-001 pipeline. Despite ongoing competitive pressures in the broader immunoglobulin market, ADMA remains confident in its full-year guidance, supported by differentiated product performance and strategic investments.